Aligos Therapeutics Inc. (ALGS) Stock Price

6.81 ▼ -0.08 (-1.16%)
Open: 6.755 Vol: 0 Day's range: 6.56 - 6.93 Aug 17, 10:44 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ALGS Technical Analysis
5 mins 30 mins Hourly Daily Weekly
NEUTRAL BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 6.76▲ 6.78▲ 6.76▲ 6.95▼ 5.52▲
MA10 6.81▲ 6.76▲ 6.78▲ 6.30▲ 5.64▲
MA20 6.81▲ 6.80▲ 6.90▼ 5.40▲ 5.87▲
MA50 6.83▼ 7.08▼ 6.58▲ 5.54▲ 7.55▼
MA100 6.94▼ 6.21▲ 5.49▲ 6.04▲ 11.10▼
MA200 6.82▼ 5.37▲ 5.61▲ 7.18▼ 16.66▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.003▼ 0.001▲ -0.056▼ 0.248▲ 0.231▲
RSI 50.641▲ 49.167▼ 50.810▲ 62.638▲ 52.761▲
STOCH 56.615     58.025     33.055     80.262▲ 42.279    
WILL %R -29.730     -29.730     -46.939     -26.703     -25.654    
CCI -8.985     56.412     8.932     64.594     147.631▲
Latest Filters Detected On ALGS
BBANDS $ALGS Bollinger Bands Expanding Set Alert
MA $ALGS Price Crossed Below MA(7) Set Alert
CDL $ALGS Doji Candlestick Pattern Detected Set Alert
Aligos Therapeutics Inc. News
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Wednesday, August 12, 2026 09:05 AM
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow ...
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Monday, July 13, 2026 01:00 AM
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday, April 24, 2026 05:00 AM
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient ...
ALGS historical stock data
date open high low close volume
17/08/26 6.755 6.93 6.56 6.82 14,331
14/08/26 6.8599 6.97 6.58 6.89 65,564
13/08/26 6.95 7.04 6.66 6.77 95,158
12/08/26 7.38 7.55 6.75 7.00 189,209
11/08/26 7.58 7.80 7.15 7.28 236,587
10/08/26 5.74 7.71 5.7301 7.65 608,392
07/08/26 5.50 6.15 5.27 5.59 335,784
06/08/26 4.18 5.60 4.18 5.51 266,652
05/08/26 4.74 4.87 4.67 4.74 71,165
04/08/26 4.68 4.80 4.61 4.75 80,557
Quote Details
52wk Low:3.98
52wk High:13.689
Vol:0
Avg Vol(3m):3.2M
1Y Chng:-36.85%
1M Chng:+11.99%
Add to Watch List
More Information
Index US Composite
Market Cap. 42.28M